Search

Methoxypolyethylene glycol 1900 and α-bromoisobutanoyl bromide were utilized for alcoholysis reaction to obtain a macromolecular initiator. Then, a simple amphiphilic diblockpolymer (mPEG-PDMAEMA) based on the initiator and dimethylaminoethyl methacrylate was synthesized through the atomic transfer radical polymerization (ATRP) method. The structures of the initiator and diblock polymer were accurately characterized using infrared spectrum and proton nuclear magnetic resonance spectroscopy (1H NMR). Cryo-transmission electron microscopy revealed the self-assembly of mPEG-PDMAEMA into vesicle-like structures in water. Upon injection of CO2 into the solution, the tertiary amine structure within PDMAEMA underwent protonation, resulting in the mPEG-PDMAEMA adopting a hydrophilic structure. Consequently, the vesicles dissociated and dispersed, forming a network-like structure in water. The protonation phenomenon was confirmed by 1H NMR, as evidenced by the shifting of alkyl hydrogen atoms near nitrogen atoms toward downfield positions.

C23H30O5, orthorhombic, P212121 (no. 19), a = 9.5489(10) Å, b = 11.1430(10) Å, c = 18.8931(10) Å, V = 2010.29(3) Å3, Z = 4, Rgt(F) = 0.0293, wRref(F2) = 0.0763, T = 100.0(2) K.

BACKGROUND: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European Union for patients ≥26 years with R/R B-ALL. After 2 years of follow-up in ZUMA-3, the overall complete remission (CR) rate (CR+CR with incomplete hematological recovery (CRi)) was 73%, and the median overall survival (OS) was 25.4 months in 78 Phase 1 and 2 patients with R/R B-ALL who received the pivotal dose of brexu-cel. Outcomes by prior therapies and subsequent allogeneic stem cell transplantation (alloSCT) are reported. METHODS: Eligible adults had R/R B-ALL and received one infusion of brexu-cel (1×10⁶ CAR T cells/kg) following conditioning chemotherapy. The primary endpoint was the CR/CRi rate per central review. Post hoc subgroup analyses were exploratory with descriptive statistics provided. RESULTS: Phase 1 and 2 patients (N=78) were included with median follow-up of 29.7 months (range, 20.7-58.3). High CR/CRi rates were observed across all prior therapy subgroups examined: 1 prior line of therapy (87%, n=15) and ≥2 prior lines (70%, n=63); prior blinatumomab (63%, n=38) and no prior blinatumomab (83%, n=40); prior inotuzumab (59%, n=17) and no prior inotuzumab (77%, n=61); and prior alloSCT (76%, n=29) and no prior alloSCT (71%, n=49). The frequency of Grade ≥3 cytokine release syndrome, neurological events, and treatment-related Grade 5 adverse events were largely similar among prior therapy subgroups.Median duration of remission (DOR) in responders with (n=14) and without (n=43) subsequent alloSCT was 44.2 (95% CI, 8.1 to not estimable (NE)) and 18.6 months (95% CI, 9.4 to NE); median OS was 47.0 months (95% CI, 10.2 to NE) and not reached (95% CI, 23.2 to NE), respectively. Median DOR and OS were not reached in responders without prior or subsequent alloSCT (n=22). CONCLUSIONS: In ZUMA-3, adults with R/R B-ALL benefited from brexu-cel, regardless of prior therapies and subsequent alloSCT status, though survival appeared better in patients without certain prior therapies and in earlier lines of therapy. Additional studies are needed to determine the impact prior therapies and subsequent alloSCT have on outcomes of patients who receive brexu-cel.

C20H26O5, orthorhombic, P212121 (no. 19), a = 5.2825(10) Å, b = 13.0652(2) Å, c = 26.4176(4) Å, V = 1823.26(5) Å3, Z = 4, R gt(F) = 0.0338, wR ref(F 2) = 0.0821, T = 150 K. CCDC No.: 2377464.

C15H22O3, orthorhombic, P212121 (no. 19), a = 7.4754(10) Å, b = 11.1287(2) Å, c = 16.1412(3) Å, V = 1,342.81(4) Å3, Z = 4, R gt(F) = 0.0344, wR ref(F 2) = 0.0921, T = 99.98(11) K.

A novel smart material is developed, which is synthesized by succinic anhydride, epoxy resin, and zinc acetylacetone hydrate. The smart material has excellent properties of self-healing, shape memory, and degradation. The experimental results of performance characterization show that the material has good thermal stability. The glass transition temperature is adjustable between 100 and 120[degrees]C, and the storage modulus can reach 20 GPa. The maximum thermal expansion at 50[degrees]C is less than 15%, the thermal expansion equilibrium time at 120[degrees]C is less than 5 min, and the maximum thermal expansion is 131%. The stress relaxation time at 120[degrees]C is more than 2 h, which can slowly self-heal on the basis of maintaining the mechanical strength. When the NaOH content is 1.5%, the degradation equilibrium can be reached in about 3 h, and the maximum degradation rate is 86%. The comprehensive performance evaluation shows that after hot rolling at 120[degrees]C/16 h, the material has no effect on the rheology and filtration properties. When plugging the fracture width of 5 * 4 mm, the pressure bearing capacity reaches 10 MPa. Its main mechanism is temperature-sensitive expansion, and the stress relaxation effect heals and blocks the micro pore throat. KEYWORDS degradable, high temperature, seal-healing, shape memory, 1 | INTRODUCTION Natural gas energy, as a clean energy with huge reserves, wide distribution, and green, has broad application prospects. However, it often faces with complex situations such as [...]